T 1149/24 (Autoimmune diseases/AMGEN) of 22.09.2025
- European Case Law Identifier
- ECLI:EP:BA:2025:T114924.20250922
- Date of decision
- 22 September 2025
- Case number
- T 1149/24
- Online on
- 1 October 2025
- Petition for review of
- -
- Application number
- 10733814.7
- IPC class
- C07K 14/55C12N 15/12A61K 38/20
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Compositions and methods of treating inflammatory and autoimmune diseases
- Applicant name
- Amgen Inc.
- Opponent name
- STRAWMAN LIMITED
Sanofi
König Szynka Tilmann von Renesse
Merck Sharp & Dohme LLC - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 108European Patent Convention R 99(2)European Patent Convention R 101(1)European Patent Convention R 103(3)(a)
- Keywords
- Admissibility of appeal - missing statement of grounds
- Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal of appellant II (opponent 4) is rejected as inadmissible.
The appeal fee of appellant I (patent proprietor) is to be refunded at 50%.